LPL Financial LLC Makes New $53,000 Investment in Aprea Therapeutics, Inc. (NASDAQ:APRE)

LPL Financial LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,052 shares of the company’s stock, valued at approximately $53,000. LPL Financial LLC owned 0.30% of Aprea Therapeutics as of its most recent SEC filing.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on APRE. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research note on Wednesday, January 15th. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday, March 25th.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $1.81 on Friday. Aprea Therapeutics, Inc. has a fifty-two week low of $1.41 and a fifty-two week high of $5.90. The firm’s 50-day simple moving average is $2.00 and its 200 day simple moving average is $3.02. The stock has a market cap of $10.00 million, a PE ratio of -0.64 and a beta of 1.04.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.20. The firm had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.15 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. As a group, analysts predict that Aprea Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Aprea Therapeutics Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.